Clinical Trial Update: Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating resveratrol's effects on cardiovascular risk markers and cognitive performance in patients with schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Resveratrol (resveratrol)

Snippet

Sponsor: Federal University of Rio Grande do Sul | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED